DBV Technologies S.A.
NASDAQ:DBVTBiotechnology
-$0.16 today
- Market cap
- $238.98M
- Beta
- -0.22
- P/E (TTM)
- -8.3
- EPS (TTM)
- -$0.39
Volume 0.17M
Average 0.24M
DBVT Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
DBV Technologies S.A.NASDAQ: DBVT
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization dips below year-ago levels
Q1 FY2026 depreciation & amortization of $900K fell 10.0% year over year, behind the +14181.8% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 30.4% from the prior quarter. Over 3 fiscal years it compounded at -37.6% a year.
Context
- Depreciation & amortization increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -10.0% toward the trailing-twelve-month pace of +14181.8%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 3.19M USD
- Year-over-year change
- +445.3%
- 4-year CAGR
- -21.4%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 3.19M | +445.3% |
| FY2024 | 2024-12-31 | (925K) | +93.4% |
| FY2023 | 2023-12-31 | (14M) | -206.4% |
| FY2022 | 2022-12-31 | 13.16M | +57.1% |
| FY2021 | 2021-12-31 | 8.38M | — |
Depreciation & Amortization vs competitors
How DBVT compares with its peers on the latest reported figures
- DBVT's LTM Mar 2026 depreciation & amortization of $3.14M is the 3rd largest of the 11 companies compared; the peer median is $672K.
- Its year-over-year change of +14181.8% is the highest of 10, against a peer median of -1.7%.
- Over three fiscal years its annual growth of -37.6% compares with a peer median of +3.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $19.68M | -2.6% | +3.0% | 28.9% | |
| LTM Mar 2026 | $3.75M | -7.8% | +14.7% | 97.6% | |
| LTM Mar 2026 | $3.14M | +14181.8% | -37.6% | — | |
| LTM Mar 2026 | $2.17M | +0.9% | +0.9% | — | |
LXEOLexeo Therapeutics, Inc. Common Stock | LTM Mar 2026 | $1.99M | -1.7% | -30.8% | — |
| LTM Mar 2026 | $674K | +14.4% | +24.6% | — | |
ENGNenGene Holdings Inc. | LTM Apr 2026 | $670K | +79.6% | +28.8% | — |
| LTM Mar 2026 | $326K | +176.0% | — | — | |
LBRXLB Pharmaceuticals Inc Common Stock | LTM Mar 2026 | $325.5K | — | +443.4% | — |
| LTM Mar 2026 | $106K | -33.8% | -39.0% | 294.4% | |
| LTM Mar 2026 | $97.21K | -103.3% | -0.7% | 0.0% | |
| Peer median (excluding DBVT) | $672K | -1.7% | +3.0% | 63.2% | |
Competitors are the stored peer set for DBVT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (97.81M) | (96.27M) | (72.73M) | (113.92M) | (146.95M) |
| Depreciation & Amortization | 8.38M | 13.16M | (14M) | (925K) | 3.19M |
| Deferred Income Tax | 184K | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 3.12M | 5.03M | 6.02M | 4.62M | 5.39M |
| Change in Working Capital | (22.77M) | 22.32M | 953K | 5.75M | 1.34M |
| Accounts Receivables | 2.15M | 0 | 0 | 0 | 0 |
| Inventory | (16.18M) | 0 | 0 | 0 | (16.11M) |
| Accounts Payables | (7.56M) | 3.46M | 8.42M | 272K | 15.83M |
| Other Working Capital | (1.19M) | 18.86M | (7.47M) | 5.48M | 1.62M |
| Other Non-Cash Items | 656K | 66K | 99K | (3K) | 15.84M |
| Operating Cash Flow | (108.24M) | (55.7M) | (79.65M) | (104.47M) | (121.18M) |
| Capital Expenditures | (918K) | (754K) | (677K) | (2.34M) | (533.64K) |
| Acquisitions (Net) | 511.01K | 7.61K | 0 | 0 | 0 |
| Purchases of Investments | (119K) | (123K) | (285K) | 0 | 0 |
| Sales of Investments | (511.01K) | 770K | 154K | 0 | 0 |
| Other Investing Activities | 604K | (611) | (131K) | 1.58M | (829.34K) |
| Investing Cash Flow | (433K) | (100K) | (808K) | (757K) | (1.37M) |
| Debt Repayment | (582.92K) | (474K) | 0 | 0 | 0 |
| Common Stock Issued | 978K | 194.59M | 6.92M | 634K | 277.04M |
| Common Stock Repurchased | 0 | 0 | (154K) | (47K) | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (121.08K) | (20K) | 0 | 0 | (854.56K) |
| Financing Cash Flow | 274K | 194.1M | 6.77M | 587K | 276.18M |
| Effect of Forex Changes | (10.65M) | (6.5M) | 5.87M | (4.27M) | 8.08M |
| Net Change in Cash | (119.05M) | 131.9M | (67.83M) | (108.91M) | 161.71M |
| Free Cash Flow | (109.16M) | (56.45M) | (80.33M) | (106.82M) | (121.18M) |
DBV Technologies S.A.
NASDAQ:DBVT
Intrinsic Alpha fair value
Locked
Current Price
$9.99
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.